Immunovant closed at $29.90 on Nov 4, up 2.96%, 33.5% below its 52-week closing high. Volume of 1.3M shares was 0.93× its 20-day average (close to normal).
Split-adjusted performance: -6.9% over one month, +4.3% over six months, +25.7% over one year.
Short interest was 18.3M shares at the Oct 15 settlement, up 4.9% from the prior report (21.1% of float, 12.3 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| IMVTImmunovant | $29.90 | +2.96% | +4.3% | — | — | — | $6.18B | |
| KODKodiak Sciences | $98.51 | −0.38% | +114.7% | — | — | — | $6.19B | Compare |
| CGONCG Oncology | $67.71 | +5.70% | −0.4% | — | −6832.8% | — | $6.00B | Compare |
| SRRKScholar Rock Holding | $46.09 | +4.80% | −2.2% | — | — | — | $5.61B | Compare |
| CRSPCRISPR Therapeutics AG | $51.78 | +3.57% | −6.0% | +1325.1% | −879.6% | — | $5.01B | Compare |
| ADPTAdaptive Biotechnologies | $26.71 | +3.53% | +85.1% | +21.5% | −55.6% | — | $4.26B | Compare |
| KRYSKrystal Biotech | $310.84 | +1.90% | +7.6% | +30.2% | 49.5% | 40.9 | $9.20B | Compare |
| TWSTTwist Bioscience | $142.58 | +1.63% | +139.5% | +23.2% | −29.6% | — | $9.45B | Compare |
| IBRXImmunityBio | $8.93 | +7.72% | +6.6% | +93.9% | −449.6% | — | $9.46B | Compare |
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
